(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Step by step instructions to Involve Compact disc Rates for Magnanimous Giving - 2The Most Compelling Innovation Developments Somewhat recently
- 3From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- 4Mars spacecraft images pinpoint comet 3I/ATLAS's path with 10x higher accuracy. This could help us protect Earth someday
- 5Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
- The Difficulties of Getting a Green Card in the US
- Investigate the Excellence of Professional flowerbeds: A Virtual Local escort
- Tablets: Upgrade Your Understanding Experience
- Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- Denny's is shutting down restaurants around the country. What's behind the closures?
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
